Secukinumab (anti-IL-17A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17A, >95%, Human IgG1, INHIBITOR of Interleukin 17A inhibitor, INHIBITOR of Interleukin 17A inhibitor

CAS: 1229022-83-6 Cat. No.: S412013

GRADE & PURITY Animal Free, Carrier Free, Recombinant, Validated, ExactAb™, Low Endotoxin, Azide Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Application

Animal Model, ELISA, Flow Cytometry, Functional Assay

Host species

Human

Reactive species

Cynomolgus monkey, Human, Rhesus monkey

Isotype

Human IgG1

Conjugation

Unconjugated

Descripción general

Secukinumab (anti-IL-17A) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab (anti-IL-17A) is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

Specifications

Product Name

Secukinumab (anti-IL-17A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17A, >95%, Human IgG1, INHIBITOR of Interleukin 17A inhibitor

Sinónimos

CTLA-8 | Cytotoxic T-lymphocyte-associated antigen 8 | IL-17 | IL-17A

Especificaciones y pureza

Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Mecanismos bioquímicos y fisiológicos

Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of the intracellular adhesion molecule-1 (ICAM-1) in fibroblasts.

Especies hospedadoras

Human

Especificidad

IL-17A

Aplicación

ELISA, Functional Assay, Flow cytometry, Kinetics (BLI), Kinetics (SPR)

Conjugación

Unconjugated

Grado

Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated

Tipo de acción

INHIBITOR

Mecanismo de acción

INHIBITOR of Interleukin 17A inhibitor

Tipo de anticuerpo

Primary antibody

Clonalidad

Recombinant

Isotipo

Human IgG1

Tipo de cadena ligera

kappa

SDS-PAGE

26.6 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 180.9 kDa, under non-reducing conditions.

Método de purificación

Protein A purified

Pureza

>95%

Fuente

CHO supernatant

Concentración

See COA

CAS

1229022-83-6

Almacenamiento y envío

Forma

Liquid

Condiciones de almacenamiento de almacenamiento

Store at -80°C,Avoid repeated freezing and thawing

Enviado en

Dry ice packs + Cold packs

Estabilidad y almacenamiento

Store at -80℃ long term (24 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Imágenes

ELISA: Secukinumab (anti-IL-17A) (S412013)

Secukinumab (anti-IL-17A) (S412013) - ELISA
Immobilized Recombinant Human IL-17A Protein at 1 μg/mL can bind Secukinumab (anti-IL-17A) (S412013) with the EC50 of 69.38 ng/mL.

SEC: Secukinumab (anti-IL-17A) (S412013)

Secukinumab (anti-IL-17A) (S412013) - SEC
The purity of Secukinumab (anti-IL-17A) (S412013) is more than 95% verified by HPLC.

Objetivos asociados (humanos)

IL17A Tclin Interleukin-17A (0 Activities)

Discover Target: IL17A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mecanismos de acción

Referencias

1. Chenmei Peng, Pan Lei, Hongying Qi, Qianjun Zhu, Chushun Huang, Ju Fu, Chengyu Zhao.  (2025)  Effect of fecal microbiota transplantation on diabetic wound healing through the IL-17A–mTOR–HIF1α signaling axis.  APPLIED AND ENVIRONMENTAL MICROBIOLOGY,      [PMID:40019272] [10.1128/aem.02019-24]